ReviewCancers2023

Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer.

E Sun Paik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.